Literature DB >> 19595598

7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.

Joëlle Azéma1, Brigitte Guidetti, Janique Dewelle, Benjamin Le Calve, Tatjana Mijatovic, Alexander Korolyov, Julie Vaysse, Myriam Malet-Martino, Robert Martino, Robert Kiss.   

Abstract

Ciprofloxacin (CP), an antibiotic has been shown to have antiproliferative and apoptotic activities in several cancer cell lines. Moreover, several reports have highlighted the interest of increasing the lipophilicity to improve the antitumor efficacy. These studies have led us to synthesize new CP derivatives of various lipophilicities and to evaluate their activity in five human cancer cell lines. With an easy and cost-efficient procedure, 31 7-((4-substituted)piperazin-1-yl) derivatives of CP were prepared that displayed IC(50) values ranging from microM to mM concentrations and are non-toxic in vivo in healthy mice as shown by their maximal tolerated dose (MTD) indices >80 mg/kg. Several derivatives displayed higher in vitro antitumor activity than parent CP however this was not dependent on the lipophilicity of the substituent. Among all synthesized derivatives, the most potent were 2 and 6h whose IC(50) values were 10 microM in three (derivative 2) or four (derivative 6h) cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19595598     DOI: 10.1016/j.bmc.2009.06.053

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Studies on the antimicrobial properties of N-acylated ciprofloxacins.

Authors:  Ryan Cormier; Whittney N Burda; Lacey Harrington; Jordan Edlinger; Karthik M Kodigepalli; John Thomas; Rebecca Kapolka; Glen Roma; Burt E Anderson; Edward Turos; Lindsey N Shaw
Journal:  Bioorg Med Chem Lett       Date:  2012-07-01       Impact factor: 2.823

2.  New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.

Authors:  Hamada H H Mohammed; Amer Ali Abd El-Hafeez; Kareem Ebeid; Aml I Mekkawy; Mohammed A S Abourehab; Emad I Wafa; Suhaila O Alhaj-Suliman; Aliasger K Salem; Pradipta Ghosh; Gamal El-Din A Abuo-Rahma; Alaa M Hayallah; Samar H Abbas
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.

Authors:  Arkady Mustaev; Muhammad Malik; Xilin Zhao; Natalia Kurepina; Gan Luan; Lisa M Oppegard; Hiroshi Hiasa; Kevin R Marks; Robert J Kerns; James M Berger; Karl Drlica
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

4.  Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice.

Authors:  Scott A LeMaire; Lin Zhang; Wei Luo; Pingping Ren; Alon R Azares; Yidan Wang; Chen Zhang; Joseph S Coselli; Ying H Shen
Journal:  JAMA Surg       Date:  2018-09-19       Impact factor: 14.766

5.  Riboswitching with ciprofloxacin-development and characterization of a novel RNA regulator.

Authors:  Florian Groher; Cristina Bofill-Bosch; Christopher Schneider; Johannes Braun; Sven Jager; Katharina Geißler; Kay Hamacher; Beatrix Suess
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

6.  Study of the cytotoxic/toxic potential of the novel anticancer selenodiazoloquinolone on fibroblast cells and 3D skin model.

Authors:  Soňa Jantová; Dominika Topoľská; Michaela Janošková; Miroslav Pánik; Viktor Milata
Journal:  Interdiscip Toxicol       Date:  2017-05-17

7.  Fluoroquinolones Suppress TGF-β and PMA-Induced MMP-9 Production in Cancer Cells: Implications in Repurposing Quinolone Antibiotics for Cancer Treatment.

Authors:  Cheng-Yi Huang; Jenq-Lin Yang; Jih-Jung Chen; Shun-Ban Tai; Yu-Hsuan Yeh; Pei-Feng Liu; Ming-Wei Lin; Chih-Ling Chung; Chun-Lin Chen
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 8.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.